Abstract:Promoting remyelination is crucial for patients with demyelinating diseases including multiple sclerosis. However, it is still a circuitous conundrum finding a practical remyelinating therapy. Electroacupuncture (EA), originating from traditional Chinese medicine (TCM), has been widely used to treat CNS diseases all over the world, but the role of EA in demyelinating diseases is barely known. In this study, we examined the remyelinating properties and mechanisms of EA in cuprizone-induced demyelinating model, a CNS demyelinating murine model of multiple sclerosis. By feeding C57BL/6 mice with chow containing 0.2% cuprizone for 5 weeks, we successfully induce demyelination as proved by weight change, beam test, pole test, histomorphology, and Western Blot. EA treatment significantly improves the neurobehavioral performance at week 7 (2 weeks after withdrawing cuprizone chow). RNA-seq and RT-PCR results reveal up-regulated expression of myelin-related genes, and the expression of myelin associated protein (MBP, CNPase, and O4) are also increased after EA treatment, indicating therapeutic effect of EA on cuprizone model. It is widely acknowledged that microglia exert phagocytic effect on degraded myelin debris and clear these detrimental debris, which is a necessary process for subsequent remyelination. We found the remyelinating effect of EA is associated with enhanced clearance of degraded myelin debris as detected by dMBP staining and red oil O staining. Our further studies suggest that more microglia assemble in demyelinating area (corpus callosum) during the process of EA treatment, and cells inside corpus callosum are mostly in a plump, ameboid, and phagocytic shape, quite different from the ramified cells outside corpus callosum. RNA-seq result also unravels that most genes relating to positive regulation of phagocytosis (GO:0050766) are up-regulated, indicating enhanced phagocytic process after EA treatment. During the process of myelin debris clearance, microglia tend to change their phenotype toward M2 phenotype. Thus, we also probed into the phenotype of microglia in our study. Immuno-staining results show increased expression of CD206 and Arg1, and the ratio of CD206/CD16/32 are also higher in EA group. In conclusion, these results demonstrate for the first time that EA enhances myelin debris removal from activated microglia after demyelination, and promotes remyelination.

Lanthionine Ketimine Ethyl Ester Accelerates Remyelination in a Mouse Model of Multiple Sclerosis

Lanthionine ketimine ester provides benefit in a mouse model of multiple sclerosis

The Anti-Aging Protein Klotho Enhances Remyelination Following Cuprizone-Induced Demyelination

Accelerated Remyelination During Inflammatory Demyelination Prevents Axonal Loss and Improves Functional Recovery

Efficacy of a benzothiazole‐based LRRK2 inhibitor in oligodendrocyte precursor cells and in a murine model of multiple sclerosis

Pharmacological treatment promoting remyelination enhances motor function after internal capsule demyelination in mice

Combination Therapy of Mesenchymal Stem Cell Transplantation and Astrocyte Ablation Improve Remyelination in a Cuprizone-Induced Demyelination Mouse Model

Low intensity repetitive transcranial magnetic stimulation enhances remyelination by newborn and surviving oligodendrocytes in the cuprizone model of toxic demyelination

Low Field Magnetic Stimulation Promotes Myelin Repair and Cognitive Recovery in Chronic Cuprizone Mouse Model

Remyelination therapies for multiple sclerosis: optimizing translation from animal models into clinical trials

Electroacupuncture Promotes Remyelination after Cuprizone Treatment by Enhancing Myelin Debris Clearance.

Leonurine Suppresses Neuroinflammation Through Promoting Oligodendrocyte Maturation

Remyelinating Pharmacotherapies in Multiple Sclerosis

Lysophosphatidic acid receptor 1 influences disease severity in a mouse model of multiple sclerosis

Effects of Lanthionine Ketimine-5-Ethyl Ester on the α-Synucleinopathy Mouse Model

Sub-clinical glutamate receptor antagonist combinations prevent progressive demyelination

Emerging myelin repair agents in preclinical and early clinical development for the treatment of multiple sclerosis

Myeloid cell-associated aromatic amino acid metabolism facilitates CNS myelin regeneration

Clinical Applications of Myelin Plasticity for Remyelinating Therapies in Multiple Sclerosis

LINGO-1 Antibody Ameliorates Myelin Impairment and Spatial Memory Deficits in Experimental Autoimmune Encephalomyelitis Mice

Therapeutic Potential of a Novel Glucagon-like Peptide-1 Receptor Agonist, NLY01, in Experimental Autoimmune Encephalomyelitis